148 related articles for article (PubMed ID: 31854219)
1. Weighted gene expression profiles identify diagnostic and prognostic genes for lung adenocarcinoma and squamous cell carcinoma.
Wu X; Wang L; Feng F; Tian S
J Int Med Res; 2020 Mar; 48(3):300060519893837. PubMed ID: 31854219
[TBL] [Abstract][Full Text] [Related]
2. Analysis of gene expression profiles of lung cancer subtypes with machine learning algorithms.
Yuan F; Lu L; Zou Q
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165822. PubMed ID: 32360590
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma.
Qu Y; Cheng B; Shao N; Jia Y; Song Q; Tan B; Wang J
Aging (Albany NY); 2020 Mar; 12(6):4757-4777. PubMed ID: 32209727
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
5. CDK1 serves as a potential prognostic biomarker and target for lung cancer.
Li M; He F; Zhang Z; Xiang Z; Hu D
J Int Med Res; 2020 Feb; 48(2):300060519897508. PubMed ID: 32020821
[TBL] [Abstract][Full Text] [Related]
6. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
7. A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas.
Li X; Shi G; Chu Q; Jiang W; Liu Y; Zhang S; Zhang Z; Wei Z; He F; Guo Z; Qi L
BMC Genomics; 2019 Nov; 20(1):881. PubMed ID: 31752667
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of an oxidative phosphorylation-related gene signature in lung adenocarcinoma.
Xu Z; Wu Z; Zhang J; Zhou R; Ye L; Yang P; Yu B
Epigenomics; 2020 Aug; 12(15):1333-1348. PubMed ID: 32787683
[No Abstract] [Full Text] [Related]
9. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
10. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
[TBL] [Abstract][Full Text] [Related]
11.
Goto D; Komeda K; Uwatoko N; Nakashima M; Koike M; Kawai K; Kodama Y; Miyazawa A; Tanaka I; Hase T; Morise M; Hasegawa Y; Kawabe T; Sato M
Cancer Invest; 2020 Apr; 38(4):240-249. PubMed ID: 32212938
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide analysis reveals alcohol dehydrogenase 1C and secreted phosphoprotein 1 for prognostic biomarkers in lung adenocarcinoma.
Shen XY; Liu XP; Song CK; Wang YJ; Li S; Hu WD
J Cell Physiol; 2019 Dec; 234(12):22311-22320. PubMed ID: 31074035
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of Aberrantly Expressed Profiles of lncRNAs and miRNAs with Associated ceRNA Network in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Dong R; Liu J; Sun W; Ping W
Pathol Oncol Res; 2020 Jul; 26(3):1935-1945. PubMed ID: 31898160
[TBL] [Abstract][Full Text] [Related]
14. Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival.
Chen RL; Zhou JX; Cao Y; Sun LL; Su S; Deng XJ; Lin JT; Xiao ZW; Chen ZZ; Wang SY; Lin LZ
Front Immunol; 2020; 11():1933. PubMed ID: 33072067
[TBL] [Abstract][Full Text] [Related]
15. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
16. Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.
Yerukala Sathipati S; Ho SY
Sci Rep; 2017 Aug; 7(1):7507. PubMed ID: 28790336
[TBL] [Abstract][Full Text] [Related]
17. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
[TBL] [Abstract][Full Text] [Related]
18. Identification of target gene and prognostic evaluation for lung adenocarcinoma using gene expression meta-analysis, network analysis and neural network algorithms.
Selvaraj G; Kaliamurthi S; Kaushik AC; Khan A; Wei YK; Cho WC; Gu K; Wei DQ
J Biomed Inform; 2018 Oct; 86():120-134. PubMed ID: 30195659
[TBL] [Abstract][Full Text] [Related]
19. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
20. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
Jiang H; Xu S; Chen C
BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
